About TEI Biosciences
TEI Biosciences is a Healthcare company based in Waltham (United States) founded in 1993, and was acquired by Integra LifeSciences in June 2015. Biomaterials and devices are developed for tissue repair and regeneration. The company has 190 employees. The company was acqui-hired. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is TEI BIOSCIENCES INC. Its competitors include Miach Orthopaedics, Rotation Medical and Cayenne Medical; 3 of its 3 listed competitors have raised funding.
Company details
TEI Biosciences was a biomedical company, develops, manufactures, markets, and sells biologic devices for the repair, reinforcement, or reconstruction of human tissues that have failed due to aging, injury, or disease in the United States and internationally. The company offers its biologic devices for soft tissue repair and regenerative applications, including dura and hernia repair, and plastic and reconstructive surgery. Its products include SurgiMend, a cellular collagen matrix derived from fetal and neonatal bovine dermis; SurgiMend-e, a family of collagen matrices for soft tissue reconstruction; SurgiMend PRS, a acellular biologic matrix designed for plastic and reconstructive surgery; PriMatrix, a dermal repair scaffold for the management of wounds; and PriMatrix Ag Antimicrobial, a dermal repair scaffold for the management of wounds, incorporating silver ions to inhibit microbial colonization of the tissue matrix. The company also offers Durepair, a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures; TissueMend, which is indicated for tendon repair surgery, including reinforcement of the rotator cuff, patella, achilles, biceps, quadriceps, or other tendons; and Xenform Soft Tissue Repair Matrix that is designed to restore vaginal form and function after a pelvic floor procedure.
- Headquarters Waltham, United States
- Employees 190
- Stage Acquired
- SectorsHealthcare
- Website teibio.com
- Social LinkedIn
- Acquired by Integra LifeSciences (Jun 2015)
- Legal Name Tei Biosciences Inc.
- Investors
- Employee Count190
- Acquired byIntegra LifeSciences
(Jun 2015)
Investors in TEI Biosciences
TEI Biosciences has secured backing from 1 investor. Prominent investors backing the company include Integra LifeSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified medical devices are developed for healthcare applications. | 1989 | integralife.com | Plainsboro, United States |
Investor details for TEI Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TEI Biosciences
2 dated milestones of TEI Biosciences across 22 years, from founding to its latest funding, stage changes and deals.
- Founded TEI Biosciences is founded.
- Exit Acquired by Integra LifeSciences.
Competitors of TEI Biosciences
TEI Biosciences has 3 listed competitors in our database, 3 of them funded. They include Miach Orthopaedics, Rotation Medical and Cayenne Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| miachortho.com | 2016 | Boston, United States | $72.5M | Bio-engineered surgical implants for connective tissue repair are developed. | ||
| rotationmedical.com | 2009 | Minneapolis, United States | $54.58M | 34 | A rotator cuff repair system is developed for disease treatment. | |
| cayennemedical.com | 2005 | Phoenix, United States | $46.3M | 54 | Soft tissue reconstruction solutions for knee and shoulder |
Detailed competitors of TEI Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Orthopedics
3 companies that operate in the same segment as TEI Biosciences (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TEI Biosciences
TEI Biosciences was founded in 1993.
TEI Biosciences is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
TEI Biosciences has 190 employees.
TEI Biosciences was a biomedical company, develops, manufactures, markets, and sells biologic devices for the repair, reinforcement, or reconstruction of human tissues that have failed due to aging, injury, or disease in the United States and internationally. The company offers its biologic devices for soft tissue repair and regenerative applications, including dura and hernia repair, and plastic and reconstructive surgery. Its products include SurgiMend, a cellular collagen matrix derived from fetal and neonatal bovine dermis; SurgiMend-e, a family of collagen matrices for soft tissue reconstruction; SurgiMend PRS, a acellular biologic matrix designed for plastic and reconstructive surgery; PriMatrix, a dermal repair scaffold for the management of wounds; and PriMatrix Ag Antimicrobial, a dermal repair scaffold for the management of wounds, incorporating silver ions to inhibit microbial colonization of the tissue matrix. The company also offers Durepair, a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures; TissueMend, which is indicated for tendon repair surgery, including reinforcement of the rotator cuff, patella, achilles, biceps, quadriceps, or other tendons; and Xenform Soft Tissue Repair Matrix that is designed to restore vaginal form and function after a pelvic floor procedure.
TEI Biosciences's top competitors include Miach Orthopaedics, Rotation Medical and Cayenne Medical.
TEI Biosciences has 1 investor. Key investors include Integra LifeSciences.
TEI Biosciences operates through Tei Biosciences Inc..
Yes. TEI Biosciences was acquired by Integra LifeSciences in June 2015.